

IMLYGIC®
(talimogene laherparepvec)

PATIENT ALERT CARD

**Please carry this card
with you at all times.**

Present this card to healthcare
professionals (doctor, nurse)
upon consultation
or hospitalisation.

This card should be folded along the dotted lines.

Patient's Name: _____

IMLYGIC® Prescriber's (Doctor's) Name: _____

Doctor's Phone Number: _____

Name of Centre/Institution (if applicable): _____

Start Date of IMLYGIC® Treatment: _____

IMLYGIC® Batch Numbers	Dates Administered
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Instructions to prescriber: Please review important safety information with your patients every time you administer IMLYGIC®.

IMLYGIC[®]

(talimogene laherparepvec)

Instructions to Patients:

If you get any side effects, talk to your doctor, pharmacist or nurse. You can also report side effects directly via the Yellow Card Scheme at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple Store. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441.

You can get more information from:

IMLYGIC[®] Package Leaflet and Patient Safety Brochure available from your doctor, online at <https://www.medicines.org.uk/emc/> or via Amgen Medical Information on 01223 436441 or at gbinfoline@amgen.com.

If you or one of your close contacts develops a herpetic lesion (for example cold sore), please call your doctor (name and phone number provided on front) and advise your close contact to call their doctor.

The herpetic lesion can be tested to determine if it is caused by IMLYGIC[®]. Acyclovir is an antiviral drug that may be used to treat the herpetic lesion caused by IMLYGIC[®], as determined by your doctor.

INSTRUCTIONS TO PRESCRIBER:

A new card is to be completed with the first administration of IMLYGIC[®]. Record the batch number for every administration of IMLYGIC[®] on this card. Please supply a new card to the patient if needed during treatment.

INFORMATION FOR HEALTHCARE PROFESSIONALS:

IMLYGIC[®] Summary of Product Characteristics is available online at <https://www.medicines.org.uk/emc/>.